Patents by Inventor Clarke Slemon
Clarke Slemon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100310540Abstract: Provided are methods of screening compounds for any aspirin-related activity other than TAFI inhibition, and also for non-inhibition of TAFI. Compounds identified by the screening methods can be used to treat, prevent or manage in a patient pain, fever, colon cancer, pancreatic cancer or an inflammatory, platelet aggregation, fibrinolytic or hemorrhagic disease or disorder. Also provided is a method of evaluating test compounds for TAFI inhibitory activity wherein the TAFI inhibitory activity of these test compounds is compared to the TAFI inhibitory activity of aspirin or its derivatives or metabolites. Further provided is a method of treating, preventing or managing in a patient, a hemorrhagic or thrombotic disease or disorder with high dose aspirin or aspirin derivatives or metabolites.Type: ApplicationFiled: June 7, 2010Publication date: December 9, 2010Inventors: Robert S. Greenfield, Seong Soo A. An, Latchezar Trifonov, Jean Vaugeois, Clarke Slemon
-
Patent number: 7767646Abstract: Provided are methods of screening compounds for any aspirin-related activity other than TAFI inhibition, and also for non-inhibition of TAFI. Compounds identified by the screening methods can be used to treat, prevent or manage in a patient pain, fever, colon cancer, pancreatic cancer or an inflammatory, platelet aggregation, fibrinolytic or hemorrhagic disease or disorder. Also provided is a method of evaluating test compounds for TAFI inhibitory activity wherein the TAFI inhibitory activity of these test compounds is compared to the TAFI inhibitory activity of aspirin or its derivatives or metabolites. Further provided is a method of treating, preventing or managing in a patient, a hemorrhagic or thrombotic disease or disorder with high dose aspirin or aspirin derivatives or metabolites.Type: GrantFiled: October 6, 2006Date of Patent: August 3, 2010Assignee: American Diagnostica, Inc.Inventors: Robert S. Greenfield, Seong Soo A. An, Latchezar Trifonov, Jean Vaugeois, Clarke Slemon
-
Publication number: 20080305508Abstract: Provided are methods of screening compounds for any aspirin-related activity other than TAFI inhibition, and also for non-inhibition of TAFI. Compounds identified by the screening methods can be used to treat, prevent or manage in a patient pain, fever, colon cancer, pancreatic cancer or an inflammatory, platelet aggregation, fibrinolytic or hemorrhagic disease or disorder. Also provided is a method of evaluating test compounds for TAFI inhibitory activity wherein the TAFI inhibitory activity of these test compounds is compared to the TAFI inhibitory activity of aspirin or its derivatives or metabolites. Further provided is a method of treating, preventing or managing in a patient, a hemorrhagic or thrombotic disease or disorder with high dose aspirin or aspirin derivatives or metabolites.Type: ApplicationFiled: October 6, 2006Publication date: December 11, 2008Inventors: Robert S. Greenfield, Seong Soo A. An, Latchezar Trifonov, Jean Vaugeois, Clarke Slemon
-
Patent number: 7316900Abstract: The present invention provides a method of regulating the expression of the urokinase type plasminogen activator (“uPA”) gene in a mammalian cell comprising the steps of: identifying a target nucleotide sequence in a gene of interest, obtaining a methylated antisense oligonucleotide sequence complementary to the target sequence, said oligonucleotide sequence having 5 methylated cytosine in place of unmethylated cytosine in the region complementary to the CpG region in the target nucleotide sequence, and exposing the cell to copies of the oligonucleotide sequence under suitable conditions, such that the oligonucleotide sequence enters the nucleus and interacts with the target sequence to promote methylation of the target nucleotide sequence.Type: GrantFiled: July 13, 2001Date of Patent: January 8, 2008Assignee: Quebepharma Recherche, Inc.Inventors: Shafaat A. Rabbani, Clarke Slemon
-
Patent number: 7119068Abstract: Provided are methods of screening compounds for any aspirin-related activity other than TAFI inhibition, and also for non-inhibition of TAFI. Compounds identified by the screening methods can be used to treat, prevent or manage in a patient pain, fever, colon cancer, pancreatic cancer or an inflammatory, platelet aggregation, fibrinolytic or hemorrhagic disease or disorder. Also provided is a method of evaluating test compounds for TAFI inhibitory activity wherein the TAFI inhibitory activity of these test compounds is compared to the TAFI inhibitory activity of aspirin or its derivatives or metabolites. Further provided is a method of treating, preventing or managing in a patient, a hemorrhagic or thrombotic disease or disorder with high dose aspirin or aspirin derivatives or metabolites.Type: GrantFiled: August 29, 2003Date of Patent: October 10, 2006Assignees: American Diagnostica, Inc., Quebepharma Recherche, Inc.Inventors: Robert S. Greenfield, Seong Soo A. An, Latchezar Trifonov, Jean Vaugeois, Clarke Slemon
-
Publication number: 20050222096Abstract: Provided are methods of screening compounds for any aspirin-related activity other than TAFI inhibition, and also for non-inhibition of TAFI. Compounds identified by the screening methods can be used to treat, prevent or manage in a patient pain, fever, colon cancer, pancreatic cancer or an inflammatory, platelet aggregation, fibrinolytic or hemorrhagic disease or disorder. Also provided is a method of evaluating test compounds for TAFI inhibitory activity wherein the TAFI inhibitory activity of these test compounds is compared to the TAFI inhibitory activity of aspirin or its derivatives or metabolites. Further provided is a method of treating, preventing or managing in a patient, a hemorrhagic or thrombotic disease or disorder with high dose aspirin or aspirin derivatives or metabolites.Type: ApplicationFiled: August 29, 2003Publication date: October 6, 2005Inventors: Robert Greenfield, Seong An, Latchezar Trifonov, Jean Vaugeois, Clarke Slemon
-
Publication number: 20040053259Abstract: The present invention provides a method of regulating the expression of the urokinase type plasminogen activator (“uPA”) gene in a mammalian cell comprising the steps of: identifying a target nucleotide sequence in a gene of interest, obtaining a methylated antisense oligonucleotide sequence complementary to the target sequence, said oligonucleotide sequence having 5 methylated cytosine in place of unmethylated cytosine in the region complementary to the CpG region in the target nucleotide sequence, and exposing the cell to copies of the oligonucleotide sequence under suitable conditions, such that the oligonucleotide sequence enters the nucleus and interacts with the target sequence to promote methylation of the target nucleotide sequence.Type: ApplicationFiled: July 31, 2003Publication date: March 18, 2004Inventors: Shafaat A Rabbani, Clarke Slemon
-
Patent number: 6703504Abstract: There are provided novel chemical compounds and their uses in the preparation of polymers and oligomers, and the preparation of such compounds. In certain embodiments there are provided dendritic polymers and oligomers, of a type having at least four polymeric or oligomeric organic chains emanating from a single chemical core, each of the chains being of substantially equal length and substantially the same chemical composition. Such compounds may be referred to as dendrimers. Also provided are novel chemical entities useful as core entities in the preparation of dentrimers. Dendrimers can recognize a core substructure to which the polymeric/oligomeric chains (“dendrons”) are covalenty attached and from which they extend with systematic branching radially outward in a three dimensional fashion, to approximately the same extent to each other. Together, core and dendrons constitute macromolecules possessing a high degree of internal structural replication attributable to the branches.Type: GrantFiled: February 11, 2002Date of Patent: March 9, 2004Inventors: Clarke Slemon, Bohumil Macel, Latchazar Trifonov, Jean Vaugeois
-
Patent number: 6677453Abstract: Polymorphic Form (I) finasteride is prepared by first forming a substantially insoluble complex of finasteride and a Group (I) or Group (II) metal salt, such as lithium bromide, and then dissociating the complex by dissolving away the salt component with water, so as to obtain substantially pure Form (I) polymorphic crystalline finasteride.Type: GrantFiled: June 18, 2002Date of Patent: January 13, 2004Assignee: Torcan Chemical LTDInventor: Clarke Slemon
-
Publication number: 20030232932Abstract: There are provided novel chemical compounds and their uses in the preparation of polymers and oligomers, and the preparation of such compounds. In certain embodiments there are provided dendritic polymers and oligomers, of a type having at least four polymeric or oligomeric organic chains emanating from a single chemical core, each of the chains being of substantially equal length and substantially the same chemical composition. Such compounds may be referred to as dendrimers. Also provided are novel chemical entities useful as core entities in the preparation of dentrimers. Dendrimers can recognize a core substructure to which the polymeric/oligomeric chains (“dendrons”) are covalenty attached and from which they extend with systematic branching radially outward in a three dimensional fashion, to approximately the same extent to each other. Together, core and dendrons constitute macromolecules possessing a high degree of internal structural replication attributable to the branches.Type: ApplicationFiled: June 5, 2002Publication date: December 18, 2003Inventors: Clarke Slemon, Bohumil Macel, Latchazar Trifonov, Jean Vaugeois
-
Patent number: 5932709Abstract: The present invention relates to chemotherapeutic agents, and more particularly, to novel analogs of camptothecin. The camptothecin analogs display increased solubility through the hydrophilicity of added non-ionic sugar substituents. In accordance with the present invention, a member from the class of novel camptothecin analogs is to be delivered in vivo as a chemotherapeutic agent to fight cancer growth in the body.Type: GrantFiled: June 16, 1997Date of Patent: August 3, 1999Assignee: University of MichiganInventors: Brian Keith Shull, Clarke Slemon, Masato Koreeda
-
Patent number: 5783702Abstract: Cisapride, i.e. cis-4-amino-5-chloro-N-?1-?3-(4 fluoro-phenoxy)propyl!-3-methoxy-4-piperidinyl!-2-methoxy-benzamide, and similar benzamide derivatives, are prepared from novel 1-aryloxyalkyl- or 1-aralkyl-3-arylcarbonyloxy-4-oxo-piperidines, by nuclear substituent re arrangement involving acyl transfer under animal forming conditions, to give the corresponding 1-aryloxyalkyl- or 1-aralkyl-3-hydroxy-4-lower alkoxy-4-arylamido piperidine. This in turn is readily converted to the corresponding 3-oxo-4-arylamido-piperidine by reaction with strong organic acid, which can then be reduced, deprotected and 3-methylated to give the final compound, e.g. cisapride.Type: GrantFiled: August 21, 1996Date of Patent: July 21, 1998Assignee: Torcan Chemical Ltd.Inventors: Yee-Fung Lu, Clarke Slemon, Raymond So, Jan Oudenes, Teng-Ko Ngooi
-
Patent number: 5677286Abstract: The present invention relates to chemotherapeutic agents, and more particularly, to novel analogs of camptothecin. The camptothecin analogs display increased solubility through the hydrophilicity of added non-ionic sugar substituents. In accordance with the present invention, a member from the class of novel camptothecin analogs is to be delivered in vivo as a chemotherapeutic agent to fight cancer growth in the body.Type: GrantFiled: April 27, 1995Date of Patent: October 14, 1997Assignee: The University of MichiganInventors: Brian K. Shull, Clarke Slemon, Masato Koreeda
-
Patent number: 5665884Abstract: Cisapride, i.e. cis-4-amino-5-chloro-N-[1-[3-(4 fluoro-phenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxy-benzamide, and similar benzamide derivatives, are prepared from novel 1-aryloxyalkyl- or 1-aralkyl-3-arylcarbonyloxy-4-oxo-piperidines, by nuclear substituent re arrangement involving acyl transfer under animal forming conditions, to give the corresponding 1-aryloxyalkyl- or 1-aralkyl-3-hydroxy-4-lower alkoxy-4-arylamido piperidine. This in turn is readily converted to the corresponding 3-oxo-4-arylamido-piperidine by reaction with strong organic acid, which can then be reduced, deprotected and 3-methylated to give the final compound, e.g. cisapride.Type: GrantFiled: August 21, 1996Date of Patent: September 9, 1997Assignee: Torcan Chemical Ltd.Inventors: Yee-Fung Lu, Raymond So, Clarke Slemon, Jan Oudenes, Teng-Ko Ngooi
-
Patent number: 5585387Abstract: Cisapride, i.e. cis-4-amino-5-chloro-N-[1-[3-(4 fluoro-phenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxy-benzamide, and similar benzamide derivatives, are prepared from novel 1-aryloxyalkyl- or 1-aralkyl-3-arylcarbonyloxy-4-oxo-piperidines, by nuclear substituent re arrangement involving acyl transfer under animal forming conditions, to give the corresponding 1-aryloxyalkyl- or 1-aralkyl-3-hydroxy-4-lower alkoxy-4-arylamido piperidine. This in turn is readily converted to the corresponding 3-oxo-4-arylamido-piperidine by reaction with strong organic acid, which can then be reduced, deprotected and 3-methylated to give the final compound, e.g. cisapride.Type: GrantFiled: October 7, 1994Date of Patent: December 17, 1996Assignee: Torcan Chemical Ltd.Inventors: Yee-Fung Lu, Raymond So, Clarke Slemon, Jan Oudenes, Teng-Ko Ngooi
-
Patent number: 5502195Abstract: Omeprazole and lansoprazole, which are chemically pyridine-benzimidazole sulfinyl compounds, are produced from the corresponding acetamide-sulfide compounds by a process of oxidation to form the amide sulfinyl compound, followed by alkaline hydrolysis to the sulfinyl carboxylate or salt, and decarboxylation.Type: GrantFiled: November 22, 1994Date of Patent: March 26, 1996Inventors: Clarke Slemon, Bob Macel
-
Patent number: 5470983Abstract: Omeprazole and lansoprazole, which are chemically pyridine-benzimidazole sulfinyl compounds, are produced from the corresponding acetamide-sulfide compounds by a process of oxidation to form the amide sulfinyl compound, followed by alkaline hydrolysis to the sulfinyl carboxylate or salt, and decarboxylation.Type: GrantFiled: July 18, 1994Date of Patent: November 28, 1995Assignee: Torcan Chemical Ltd.Inventors: Clarke Slemon, Bob Macel
-
Patent number: 5374730Abstract: Omeprazole and lansoprazole, which are chemically pyridine-benzimidazole sulfinyl compounds, are produced from the corresponding acetamide-sulfide compounds by a process of oxidation to form the amide sulfinyl compound, followed by alkaline hydrolysis to the sulfinyl carboxylate or salt, and decarboxylation.Type: GrantFiled: November 4, 1993Date of Patent: December 20, 1994Assignee: Torcan Chemical Ltd.Inventors: Clarke Slemon, Bob Macel
-
Patent number: 5371240Abstract: 3-substituted thiophene compounds contaminating the analogous 2-substituted thiophene compounds, e.g. 3-acetylthiophene contaminating 2-acetyl thiophene, are removed by a selective electrophilic substitution process, e.g. bromination, followed by fractional distillation. It has been found that electrophilic substitution as exemplified by bromination is highly selective towards the 3-substituted thiophenes, yielding compounds of significantly higher molecular weights for separation purposes, to give high purity 2-substituted thiophene compounds.Type: GrantFiled: November 30, 1992Date of Patent: December 6, 1994Assignee: Torcan Chemical Ltd.Inventor: Clarke Slemon